Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
98,567,360
-
Number of holders
-
114
-
Total 13F shares, excl. options
-
59,892,346
-
Shares change
-
-5,496,612
-
Total reported value, excl. options
-
$612,088,367
-
Value change
-
-$15,900,636
-
Put/Call ratio
-
9.5%
-
Number of buys
-
63
-
Number of sells
-
-38
-
Price
-
$10.22
Significant Holders of ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) as of Q1 2024
132 filings reported holding SPRY - ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share as of Q1 2024.
ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) has 114 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 59,892,346 shares
of 98,567,360 outstanding shares and own 60.76% of the company stock.
Largest 10 shareholders include DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (11,077,927 shares), RA CAPITAL MANAGEMENT, L.P. (10,860,977 shares), ORBIMED ADVISORS LLC (9,240,887 shares), SR ONE CAPITAL MANAGEMENT, LP (4,012,903 shares), FRANKLIN RESOURCES INC (2,950,963 shares), VANGUARD GROUP INC (2,886,455 shares), BlackRock Inc. (2,658,239 shares), K2 PRINCIPAL FUND, L.P. (2,219,131 shares), Nextech Invest Ltd. (1,910,029 shares), and STATE STREET CORP (1,604,550 shares).
This table shows the top 114 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.